Lantheus Beats Q3 Estimates With $1.68 Adjusted EPS, Revenue Up 1.5%
LNTH has more than doubled off its 52-week low of $50.155 on light trading volume (0.3× avg).
Summary
Lantheus beat on both lines: adjusted EPS of $1.68 against a $1.24 consensus, and revenue of $389.91 million versus $359.76 million expected, up 1.5% year over year. GAAP EPS was only $0.33, dragged by $31.0 million of IPR&D impairments and $24.3 million of approval milestone charges disclosed in the 10-Q filed today. This is the fourth straight quarter of beats, though the mean analyst estimate had fallen about 3.1% over the past three months. The stock trades near $101 against a $105 median price target and a 'hold' consensus, and the pending $8 billion Curium acquisition at $102.50 cash plus up to $12 in CVRs caps the upside — the FTC Second Request from October 22 remains the swing factor for closing.
At the time of this announcement, LNTH was trading at $100.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $50.16 to $111.86. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.